Shop

Author at Microdose

Microdose NewsDesk

Microdose's editorial department brings you the latest news and industry insights.

psychedelic news

Don’t Miss

23 Oct 2023

News You Might Have Missed: Oct 23rd, 2023

Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine news to help you catch up and stay informed....

By Microdose NewsDesk
news

Don’t Miss

16 Oct 2023

News You Might Have Missed: Oct 16th, 2023

Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine news to help you catch up and stay informed....

By Microdose NewsDesk
cybin deal

Finance

13 Oct 2023

Cybin Shareholders Approve Acquisition of Small Pharma

Cybin shareholders approve the acquisition of Small Pharma with 99.4% of the vote....

By Microdose NewsDesk
psychedelic news

Don’t Miss

9 Oct 2023

News You Might Have Missed: Oct 9th, 2023

Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine news to help you catch up and stay informed....

By Microdose NewsDesk

Join Our Newsletter for Exclusive Updates, Stories, and More

california mushroom

Law & Politics

5 Oct 2023

California Passes Bill Allowing Doctors to Prescribe Psychedelics If Federally Re-Scheduled

California Governor Gavin Newsom has signed a bill that allows doctors to legally prescribe psychedelics when re-scheduled by the federal government....

By Microdose NewsDesk

Industry

4 Oct 2023

GH Research: Updates on Clinical Development Programs

5-MEO-DMT developer GH Research has provided an update on its main clinical programs....

By Microdose NewsDesk
news psychedelic

Don’t Miss

2 Oct 2023

News You Might Have Missed: Oct 2, 2023

Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine news to help you catch up and stay informed....

By Microdose NewsDesk

Industry

28 Sep 2023

Numinus Announces $10 Million Equity Program

Numinus has announced an at-the-market equity offering program that allows the company to issue and sell up to $10,000,000 (CAD) of common shares....

By Microdose NewsDesk
FDA

Industry

27 Sep 2023

FDA Accepts PharmaTher’s New Drug Application for KETARX™ (Ketamine)

The FDA has accepted the company’s Abbreviated New Drug Application for KETARX™ (racemic ketamine). The goal date for this priority original ANDA of April 29, 2024....

By Microdose NewsDesk

Follow us on social

Latest News

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

You Might Also Like

17 Dec 2025

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

If 2024 was the year the psychedelic field learned how hard “approval ready” really is, 2025 was the year it began behaving accordingly. The past twelve months were less about...

By Madison Roberts

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts

15 Oct 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being...

By Madison Roberts
WordPress Ads
No Result
View All Result

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.